RxDoctor Payments Data

Amanda Gibson

Nurse Practitioner · Colorado Springs, CONPI 1023773884

Payments from drug & device makers

$991in general payments, 2019–2025

Across 32 payments — averaging $30.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genmab U.S., Inc.$272
  • GSK$223
  • Merck$147
  • AstraZeneca$136
  • AbbVie$65
  • Caris MPI, Inc.$58
  • plus $91 from 3 others

What the payments were for

  • Food & beverage$991100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$991 in reported general payments places this provider in the 80th percentile of 1,384 nurse practitioner providers in Colorado.

See all nurse practitioner providers in Colorado

Medicare billing

Part B allowed, 2024
$38,263
Medicare patients
135
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib69$1,125,683
EliquisApixaban17$18,881
Estradiol15$1,299
Megestrol Acetate25$847
Gabapentin43$681
Lidocaine-PrilocaineLidocaine/Prilocaine39$660
Prednisolone Acetate14$616
Prochlorperazine Maleate48$560
Dexamethasone28$556
Pregabalin15$394
Potassium Chloride24$367
Omeprazole29$362
Duloxetine Hcl17$299
Ondansetron Hcl41$279
Anastrozole11$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$136$1,125,68369 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,384 nurse practitioner providers in Colorado.

Other nurse practitioner in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →